effectiveness of neuroimgaing in the early diagnosis of neurodegeneration

effectiveness of neuroimgaing in the early diagnosis of neurodegeneration - effectiveness of neuroimgaing in the early diagnosis of neurodegeneration

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029247

Enrollment

Registered

2017-11-15

Start date

2016-11-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neurodegeneration

Interventions

resting functional imaging

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who are suspected of neurodegenerative disease or who are diagnosed as neurodegenerative diseases. Specifically, it includes Alzheimer's dementia, Parkinson's disease, Lewy body dementia, Parkinson's disease accompanied by dementia, Progressive supranuclear palsy, Corticobasal nuclear degeneration, Multiple system atrophy, Amyotrophic lateral sclerosis and Frontotemporal dementia

Exclusion criteria

Exclusion criteria: Underage. Patients who are complicated with cerebral organic disease. Patints who merge substance-related disorders (drug dependence etc.). Patients who have complications of serious diseases, or patients who have a history of these diseases. Patient with claustrophobia. Patients who has pacemaker, body metal, tattoo. Patients who may be pregnant or who are breastfeeding. In addition, patients judged by a doctor to be inappropriate as subjects.

Design outcomes

Primary

Measure	Time frame
features of neuroimaging in patients with early stage of neurodegeneration	—

Countries

Japan

Contacts

Public ContactAya Ogura

Nagoya University Graduate School of Medicine Neurology

neurology@med.nagoya-u.ac.jp052-744-2391

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026